Program
GHZ339
A development code.
In Novartis's pipeline, IL-13, IL18 inhibitor
. Its studies are mostly in Dermatitis, Atopic, led by Novartis.
Furthest: phase 2, since Apr 25, 20251 company-led study, 1 open or runningNext primary completion: Nov 27, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 11 open or running | phase 2since Apr 25, 2025 | Apr 25, 2025 | Nov 27, 2028phase 2 · NCT06947993 |
- Named in Novartis’s own pipeline as
GHZ339
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 25, 2025First study: phase 2 study in Dermatitis, AtopicFirst studyNCT06947993 · 224 planned · United States, Argentina, Canada and more
Ahead
- Nov 27, 2028Primary completion: phase 2 study in Dermatitis, AtopicNCT06947993
TargetBeta
“IL-13, IL18 inhibitor”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06947993Dermatitis, Atopic · United States, Argentina, Canada and more | 2 | Recruiting | Nov 27, 2028 | 224 |
How it is read
Names in the registry
- “GHZ339”, 1 entry
Codes read as this program: GHZ339.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.